A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct Cancer
Primary Purpose
Gallbladder Cancer, Bile Duct Cancer
Status
Unknown status
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Fluorouracil implant
Sponsored by
About this trial
This is an interventional treatment trial for Gallbladder Cancer
Eligibility Criteria
Inclusion Criteria:
- The patients with gallbladder and bile duct cancer diagnosis by surgical exploration, or intraoperative frozen biopsy (Annex 2).
- Aged 18 to 70 years old, male or female, body condition score generally ECOG 0~2, expected survival ≥ 3 months.
- Subjects were no major organ dysfunction, blood, liver, kidney and heart function was normal, the specific requirements of laboratory indicators:
Blood: WBC count > 3.0 × 109 / L, Platelet count> 100 × 109 / L, Hb > 8.0g/dl. Liver function:serum bilirubin less than 1.5 times the upper limit of normal; ALT and AST less than 3 times the upper limit of normal.
Renal function: creatinine less than 1.5 times the upper limit of normal.
- Participants have used other chemotherapy drugs, subject to the 30-day washout period before proceeding with the test.
- Patients had no anaphylactic reaction with oxaliplatin and fluorouracil in the past.
- Patients who can understand the circumstances of this study and signed informed consent.
Exclusion Criteria:
- Currently is receiving effective treatment;
- Pregnancy, breast-feeding patients;
- Primary brain tumors or central nervous system metastatic tumor is not controlled;
- Patients received chemotherapy, radiotherapy, biological therapy, other drugs or instrument therapy 30 days before enrollment.
- Patients with purulent and chronic infected wounds which delayed healing.
- Patients with liver, kidney and heart failure and coronary heart disease, angina, myocardial infarction, arrhythmia, cerebral thrombosis, stroke and other serious cardiovascular and cerebrovascular disease;
- Patients has a history of mental illness and difficult to control;
- Patients who was considered inappropriate to participate in the trials by the researchers.
Sites / Locations
- Eastern Hepatobiliary Surgery HospitalRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Fluorouracil implant
Arm Description
Outcomes
Primary Outcome Measures
duration of survival after operation
Secondary Outcome Measures
disease free survival
Full Information
NCT ID
NCT01317069
First Posted
March 15, 2011
Last Updated
March 15, 2011
Sponsor
Simcere Pharmaceutical Co., Ltd
Collaborators
Eastern Hepatobiliary Surgery Hospital
1. Study Identification
Unique Protocol Identification Number
NCT01317069
Brief Title
A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct Cancer
Official Title
A Randomized, Open, Prospective Clinical Research Programs of Fluorouracil Implant (Sinofuan) to Improve Surgical Gallbladder Cancer and Bile Duct Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
March 2011
Overall Recruitment Status
Unknown status
Study Start Date
June 2010 (undefined)
Primary Completion Date
December 2012 (Anticipated)
Study Completion Date
April 2013 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Simcere Pharmaceutical Co., Ltd
Collaborators
Eastern Hepatobiliary Surgery Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Through clinical practice, to explore if the application of Fluorouracil implant could effectively delay the local tumor recurrence and improvement the postoperative survival time in patients with gallbladder cancer and bile duct cancer.
Detailed Description
Major Objective Through clinical practice, to explore if the application of Fluorouracil implant could effectively delay the local tumor recurrence and improvement the postoperative survival time in patients with gallbladder cancer and bile duct cancer.
Secondary objective
1) If Fluorouracil implants application in clinical surgery could lead to the incidence of complications increased in biliary-enteric anastomosis.
2)Assess drug safety according to drug-related clinical and / or laboratory adverse events.
3)Observe the postoperative complication rate of Fluorouracil implants. 4)Observe the quality of life of patients used Fluorouracil implants.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gallbladder Cancer, Bile Duct Cancer
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Fluorouracil implant
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Fluorouracil implant
Other Intervention Name(s)
Sinofuan
Intervention Description
Before the abdomen was closed, fluorouracil implant 1000mg was sprayed evenly on the surface of tumor resection area, and some of the drugs were put into mesenteric root based on the location
Primary Outcome Measure Information:
Title
duration of survival after operation
Time Frame
3 years
Secondary Outcome Measure Information:
Title
disease free survival
Time Frame
1 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
The patients with gallbladder and bile duct cancer diagnosis by surgical exploration, or intraoperative frozen biopsy (Annex 2).
Aged 18 to 70 years old, male or female, body condition score generally ECOG 0~2, expected survival ≥ 3 months.
Subjects were no major organ dysfunction, blood, liver, kidney and heart function was normal, the specific requirements of laboratory indicators:
Blood: WBC count > 3.0 × 109 / L, Platelet count> 100 × 109 / L, Hb > 8.0g/dl. Liver function:serum bilirubin less than 1.5 times the upper limit of normal; ALT and AST less than 3 times the upper limit of normal.
Renal function: creatinine less than 1.5 times the upper limit of normal.
Participants have used other chemotherapy drugs, subject to the 30-day washout period before proceeding with the test.
Patients had no anaphylactic reaction with oxaliplatin and fluorouracil in the past.
Patients who can understand the circumstances of this study and signed informed consent.
Exclusion Criteria:
Currently is receiving effective treatment;
Pregnancy, breast-feeding patients;
Primary brain tumors or central nervous system metastatic tumor is not controlled;
Patients received chemotherapy, radiotherapy, biological therapy, other drugs or instrument therapy 30 days before enrollment.
Patients with purulent and chronic infected wounds which delayed healing.
Patients with liver, kidney and heart failure and coronary heart disease, angina, myocardial infarction, arrhythmia, cerebral thrombosis, stroke and other serious cardiovascular and cerebrovascular disease;
Patients has a history of mental illness and difficult to control;
Patients who was considered inappropriate to participate in the trials by the researchers.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yongjie Zhang, MD
Phone
86-021-81875271
First Name & Middle Initial & Last Name or Official Title & Degree
Wenlong Yu, MD
Phone
86-021-81875272
Facility Information:
Facility Name
Eastern Hepatobiliary Surgery Hospital
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yongjie Zhang, MD
Phone
86-021-81875271
First Name & Middle Initial & Last Name & Degree
Wenlong Yu, MD
Phone
86-021-81875272
First Name & Middle Initial & Last Name & Degree
Yongjie Zhang, MD
12. IPD Sharing Statement
Learn more about this trial
A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct Cancer
We'll reach out to this number within 24 hrs